Q-omics provides the consensus-scored MARCHF2 profile across patient tissues and cancer cell-line models. MARCHF2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MARCHF2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MARCHF2 RNA expression shows 17,765 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where MARCHF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCHF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCHF2 survival associations across molecular data types. MARCHF2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCHF2 RNA expression–survival associations across cancer types. High MARCHF2 expression shows unfavorable associations in READ, but favorable associations in HNSC, CESC, UCEC, LUAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MARCHF2 RNA expression.
This table summarizes MARCHF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MARCHF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCHF2 shows lower tumor expression in THCA, LUSC, BLCA and LUAD and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher MARCHF2 RNA expression in tumor versus normal tissue (log2 FC = +0.645, t-test p < 0.001).
This table shows molecular features associated with MARCHF2 in patient tissues and cancer cell lines. In patient samples, MARCHF2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MARCHF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
